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Cloning of the T-cell receptor genes is a critical step when generating
T-cell receptor transgenic mice. Because T-cell receptor molecules are
clonotypical, isolation of their genes requires reverse transcriptase-
assisted PCR using primers specific for each different Vα or Vß genes
or by the screening of cDNA libraries generated from RNA obtained
from each individual T-cell clone. Although feasible, these approaches
are laborious and costly. The aim of the present study was to test the
application of the non-palindromic adaptor-PCR method as an alter-
native to isolate the genes encoding the T-cell receptor of an antigen-
specific T-cell hybridoma. For this purpose, we established hybrido-
mas specific for trans-sialidase, an immunodominant Trypanosoma
cruzi antigen. These T-cell hybridomas were characterized with re-
gard to their ability to secrete interferon-γ, IL-4, and IL-10 after
stimulation with the antigen. A CD3+, CD4+, CD8- interferon-γ-
producing hybridoma was selected for the identification of the vari-
able regions of the T-cell receptor by the non-palindromic adaptor-
PCR method. Using this methodology, we were able to rapidly and
efficiently determine the variable regions of both T-cell receptor
chains. The results obtained by the non-palindromic adaptor-PCR
method were confirmed by the isolation and sequencing of the com-
plete cDNA genes and by the recognition with a specific antibody
against the T-cell receptor variable ß chain. We conclude that the non-
palindromic adaptor-PCR method can be a valuable tool for the
identification of the T-cell receptor transcripts of T-cell hybridomas
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Introduction
Transgenic mice expressing specific T-
cell receptors (TCR) are a valuable tool for
the study of the immune responses to auto-
antigens, infectious agents and neoplastic
cells (for reviews, see Refs. 1-6). A critical
step when generating these transgenic mice
is the isolation of the TCR genes. Because
TCR molecules are clonotypical, isolation
of these genes requires the identification of
the individual TCR expressed by a T-cell
clone or hybridoma. This can be accom-
plished using a panel of TCR-specific mono-
clonal antibodies. Although monoclonal anti-
bodies are available for the identification of
the different Vß chains of the mouse TCR,
antibodies specific for many of the murine
Vα chains do not exist. Alternatively, clon-
ing can be accomplished by reverse tran-
scriptase-assisted PCR using primers specif-
ic for each different Vα or Vß genes or by
the screening of cDNA libraries generated
from RNA obtained from each individual T-
cell clone. Although feasible, these ap-
proaches are laborious and costly.
In 1992, Chen and Platsoucas (7) devel-
oped the non-palindromic PCR method for
the amplification of transcripts with variable
or unknown 5' ends, such as TCR and immu-
noglobulins. Among the advantages of this
methodology is the fact that only one 5' end
extension primer is required. Since it was
first described, this methodology has been
successfully used to clone the genes encod-
ing TCR transcripts of T cells isolated from
humans and mice (8-12).
Chagas’ disease, caused by the proto-
zoan parasite Trypanosoma cruzi, afflicts 16
to 18 million people in Latin America (13).
The cell-mediated immune response (CMI)
participates in multiple aspects of Chagas’
disease. During the acute phase of infection
both CD4 and CD8 T cells have been de-
scribed as important mediators of protective
immunity. Type 1 cells (Th1 and Tc1) are
thought to mediate protective immunity in
part by their ability to secrete interferon-γ
(IFN-γ) (14). During the chronic phase of
the disease, most individuals have a strong
CMI to parasite antigens. These T cells may
help to maintain the low levels of parasite-
mia preventing the reactivation of acute in-
fection (15). On the other hand, type 1 CMI
may be the cause of heart damage during the
chronic phase of infection (16,17).
T. cruzi trypomastigotes express an en-
zyme denominated trans-sialidase (TS) on
their surface. This enzyme is required for the
parasite to obtain sialic acid from host gly-
coproteins (18). Serological studies have
shown that TS is highly immunogenic dur-
ing natural human infection with T. cruzi.
Almost all individuals develop antibodies
that recognize an epitope composed of amino
acid repetitions located at the carboxy-ter-
minal region of TS (19). Chagasic patients
also generate antibodies specific for the N-
terminal region of TS that strongly inhibit its
enzymatic activity (20-22).
In addition to antibodies, the catalytic
domain of TS induces type 1 CMI in chagas-
ic patients (23). The role of CMI specific for
the catalytic domain of TS was studied dur-
ing acute infection in mice. Immunization
with DNA vaccines elicited strong type 1
CMI and protective immunity against acute
infection in BALB/c or C57BL/6 mice (24-
26). These experiments provided strong ev-
idence that CMI to TS plays a protective role
during acute T. cruzi infection. Neverthe-
less, the participation of CMI to TS during
the chronic phase of infection is still unclear.
To study this problem, we will need more
powerful experimental models using trans-
genic CD4 and/or CD8 T cells specific for
TS. The first step toward the generation of
these transgenic animals is the isolation of
TCR genes specific for the antigen. To this
end, in the present study we established and
characterized T-cell hybridomas specific for
TS. Using these T-cell hybridomas, we de-
termined whether the non-palindromic adap-
tor (NPA)-PCR method would be able to
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easily identify the TCR transcripts.
Material and Methods
Animals
Female 5- to 8-week-old BALB/c mice
were provided by CEDEME-UNIFESP.
Trans-sialidase recombinant protein
production
Recombinant TS was produced in E.
coli transformed with the plasmid pTScat7
(27). The purity of recombinant TS was
determined by sodium dodecyl sulfate 10%
polyacrylamide gel electrophoresis. A single
band of 70 kDa was visualized in the gel.
Protein concentration was estimated by the
method of Bradford (BioRad, Hercules, CA,
USA).
Immunization of mice and culture of lymph
node cells
BALB/c mice were immunized with 25
µg of purified recombinant TS emulsified in
complete Freund’s adjuvant (Sigma, St.
Louis, MO, USA). The emulsion was in-
jected subcutaneously into the two hind foot-
pads. Two weeks later, inguinal and popliteal
lymph nodes (LN) were collected. LN cells
(3 x 106/mL) were then cultured in RPMI
medium (Invitrogen, Carlsbad, CA, USA)
supplemented with 10 mM HEPES, 2 g/L
sodium bicarbonate, 2 mM L-glutamine, 50
µM 2-mercaptoethanol, 1 mM sodium pyru-
vate, 1% (v/v) of the nonessential amino
acid solution, 1% (v/v) MEM vitamin solu-
tion (all purchased from Invitrogen), 100 U
penicillin and streptomycin per mL (Sigma),
10 µg/mL recombinant TS, 20 units/mL re-
combinant human IL-2, and 2% (v/v) inacti-
vated normal human serum. The cultures
were maintained for 5 days at 37ºC in an
atmosphere containing 5% CO2 and then
harvested and used for fusion.
Fusion and screening of the T-cell
hybridomas
Specific LN cells and BWα-ß-thymoma
cells (kindly provided by Dr. P. Marrack,
University of Colorado Health Science Cen-
ter, CO, USA) were mixed at a 5:1 ratio. One
milliliter FCS-free MEM (Invitrogen) con-
taining 50% polyethylene glycol 1450 solu-
tion (w/v, Sigma) was added to the cell pellet
under continuous gentle shaking at 37ºC.
After 1 min at 37oC, 50 mL MEM was
slowly added. Cells were centrifuged at 250
g for 6 min. The cells were resuspended in
MEM supplemented with 2.86 g/L sodium
bicarbonate, 0.6 g/L D-dextrose, 2 mM L-
glutamine, 30 µM 2-mercaptoethanol, 1 mM
sodium pyruvate, 1.1% (v/v) of the nones-
sential amino acid solution, 0.3% (v/v) es-
sential amino acid solution, 80 U/mL peni-
cillin G, 60 U/mL streptomycin sulfate (10%
S-MEM), and 10% FCS (HyClone, Logan,
UT, USA). Serial dilutions were made with
this cell suspension. Cloning was achieved
by limiting dilution. One hundred microli-
ters of the suspension was poured onto a 96-
well microplate and the remaining cell sus-
pension was diluted 1:4, 1:16, and 1:64.
Each dilution was poured onto a 96-well
microplate. The cultures were maintained at
37ºC in an atmosphere containing 5% CO2.
After 48 h, 50 µL 10% S-MEM supple-
mented with 3X HAT (Invitrogen) was added
to each well. Every 5 days, 100 µL 10% S-
MEM supplemented with 1X HAT/well was
exchanged. If cell proliferation was observed,
cells were transferred to 24-well plates and
further expanded. Two weeks after fusion,
the medium was changed to 10% S-MEM
supplemented with 1X HAT (Invitrogen)
and subsequently changed to 10% S-MEM.
Established clones were tested for reactivity
in the presence of the gene.
Cytokine production by cell hybridomas
For screening, 1 x 105 T-cell hybridoma
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cells and 1 x 106 syngeneic BALB/c spleen
cells were co-cultured in the presence or
absence of 10 µg/mL recombinant TS in
10% S-MEM. After 3 days, the supernatants
were collected and the cytokine concentra-
tion was estimated by capture ELISA using
antibodies purchased from Pharmingen (San
Diego, CA, USA) exactly as described by
Rodrigues et al. (28).
Fluorescence-activated cell sorting analysis of
the T-cell hybridomas
Phenotypic analyses of hybridomas were
carried out by fluorescence-activated cell
sorting (FACS) using a Facscalibur Cytom-
eter (Becton Dickinson, Mountain View, CA,
USA). Hybridomas (106 cells) were incu-
bated on ice for 45 min with hybridoma
supernatants. Monoclonal antibodies anti-
CD4 (GK1.5, rat IgG2), anti-CD8 (2.43, rat
IgG2), anti-CD44 (KM-102, rat IgG), and
anti-CD3 (145-2C11, hamster IgG) were
used. After two washes, cells were incubated
with fluorescein-isothiocyanate (FITC)-
labeled goat anti-rat immunoglobulin G
(KPL) or FITC-labeled goat anti-hamster
IgG (KPL) for an additional 45 min on ice,
washed, and fixed in PBS containing 1% (w/
v) paraformaldehyde. FITC-labeled anti-
TCR ß chain (H57-597, Pharmingen) or anti-
Vß6 TCR (RR4-7, Pharmingen, kindly pro-
vided by Dr. Milena B.P. Soares, FIOCRUZ,
Brazil) was used as described above without
secondary antibody incubation.
Amplification, cloning and sequencing of the
α and ß variable segment genes of the TCR
Hybridoma 09 RNA was purified using
TRIzol (Invitrogen) according to manufac-
turer instructions. RNA was precipitated with
ethanol, washed, and resuspended in nu-
clease-free water. The NPA-PCR method
was used for the amplification of TCR tran-
scripts. Briefly, 5 µg of total RNA from
hybridoma 09 was used as template for
double-stranded cDNA synthesis using ei-
ther the Cα3-NotI or Cß3-NotI primer (Table
1) and Superscript (Invitrogen). NPA (Table
1) were ligated onto the ends of the double-
stranded cDNA, resulting in the addition of
Table 1. Primers used in the present study.
Primers Nucleotide sequences
TCR α chain primers
mCα3-Not Ia 5’ - TGCGGCCGCGGTGAAGCTTGTCTGGTTG-3'
mCα2 5’ - CCAGCACAGTTTTGTGAGTG-3'
mCα1 5’ - AACAGGCAGAGGGTGCTGTCCTG-3'
mCαS (probe) 5’ - CCGAGGATCTTTTAACTGGTACACAGCAGGTTCTGGG-3'
Foward-SalI α chaina 5’ - GTCGACATGCACAGCCTCCTAGGG-3'
Reverse-BamHI α chaina 5’ - GGATCCTCAACTGGACCACAGCCT-3'
TCR ß chain primers
mCß3-Not Ia 5’ - TGCGGCCGCTGTCCTCCTCTGAAAGCCCATGGA-3'
mCß2 5’ - TGCTCAGGCAGTAGCTATAATTGCTCTCC-3'
mCß1 5’ - GCACACGAGGGTAGCCTTTTGT-3'
mCßS (probe) 5’ - ACAAGGAGACCTTGGGTGGAGTCACATTTCTCAGATCCTC-3'
Forward-SalI ß chaina 5’ - GTCGACATGAACAAGTGGGTTTTCTG-3'
Reverse-BamHI ß chaina 5’ - GGATCCTCATGAATTCTTTCTTTTGAC-3'
Adaptor primer 5’ - AATTCGAACCCCTTCG-3'
Ligated adaptor 5’ - AATTCGAACCCCTTCG-3'
3’ - GCTTGGGGAAGCp-5'
aUnderlined sequences represent restriction enzyme sites present in the oligonucleotides.
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the adaptors at both the 5' and 3' ends. After
the ligation was completed, the adaptor was
removed from the 3' end by NotI restriction
nuclease digestion, but was retained at the 5'
end. A single strand of the adaptor, called
adaptor primer (Table 1), was used as a
sense 5' end amplification primer for both
rounds of amplification performed. Two Cα
primers, designated mCα2 and mCα1, and
two Cß primers, designated mCß2 and mCß1
(Table 1), were used as 3' anti-sense amplifi-
cation primers for the first and second am-
plification reactions, respectively. mCα1 and
mCß1 were located 5' to the primers mCα2
and mCß2 used for the first amplification.
The products resulting from the second ampli-
fication were sized ~500 bp to the TCR α
chain, and ~600 bp to the TCR ß chain. Each
DNA band was purified and ligated into the
pMOSblue cloning vector. The transforma-
tion resulted in 24 colonies of the TCR α chain
and 26 of the TCR ß chain. Twenty colonies of
each chain were screened by colony hybrid-
ization with either the 32P-labeled mCαS or
mCßS probe (Table 1). Plasmids containing
inserts representing each TCR chain were se-
quenced. Automatic sequencing of double-
stranded DNA was performed using the
BigDye Terminator Cycle Sequencing kit (Per-
kin-Elmer, Foster City, CA, USA) and an ABI
PRISM 377 sequencer (Perkin-Elmer). U19
and T7 oligonucleotides (Invitrogen) present
in the flanking regions of the pMOSblue vec-
tor were used. The comparison of the nucleic
acid and the deduced amino-acid sequences
obtained with the GenBank data base and
NCBI/BLAST software allowed the identifi-
cation of both TCR chains.
Amplification, cloning and sequencing of the
genes encoding complete cDNA of the TCR α
and ß chains
The cDNA reaction was performed with
5 µg of total RNA from hybridoma 09 using
the ThermoScript RT-PCR system (Invitro-
gen). The oligo (dT) primer supplied in the
kit was used for the first strand cDNA reac-
tion. Primers specific for the variable re-
gions and constant regions of each TCR
chain (Table 1) were used to amplify the
genes encoding the complete cDNA of α
and ß chains. The products of amplification
were sized ~800 or ~900 bp in the case of α
or ß chain cDNA fragments, respectively.
These PCR products were cloned into
pMOSblue and sequenced.
Results
Characterization of T-cell hybridomas
specific for Trypanosoma cruzi trans-sialidase
Twenty clones of T-cell hybridomas were
established after fusion of LN cells and
BWα-ß-thymoma cells. These hybridomas
were stimulated in vitro with recombinant
TS in the presence of syngeneic spleen cells.
The culture supernatants were tested for the
presence of cytokines. Eight hybridomas pro-
duced more than 1.2 ng/mL IFN-γ. In con-
trast, only one hybridoma produced 0.065 or
0.660 ng IL-4 or IL-10, respectively (Table
2). By FACS analysis, all hybridomas ex-
pressed CD4 and CD3 but none expressed
the CD8 surface marker. As shown in Figure
1, T-cell hybridomas H09, H10, H21, and
H26 expressed CD3 and CD4 but not CD8.
All four hybridomas expressed the TCR ß
chain and CD44. Control cells (BWα-ß-)
did not express CD3, CD4, CD8, or TCR ß
(Figure 1).
Identification of TCR transcripts by NPA-PCR
The NPA-PCR method was used for the
amplification of TCR transcripts from hy-
bridoma 09. The alignment of three clones
identified the α chain as the TCRAV18S2
variable segment and TCRAJ17 junctional
segment. The alignment of two clones of the
ß chain identified TCRBV6S19 as the vari-
able region and TCRBJ1S1 as the junctional
region. The sequences obtained by NPA-
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Table 2. Cytokine production by T-cell hybridomas after stimulation with recombinant trans-sialidase.
Clones IFN-γ (ng/mL) IL-4 (ng/mL) IL-10 (ng/mL)
APC TS APC TS APC TS
01 ≤0.015 0.102 ± 0.117 ≤0.015 ≤0.015 ≤0.015 ≤0.015
05 0.072 ± 0.039 3.212 ± 0.275 ≤0.015 ≤0.015 ≤0.015 ≤0.015
08 ≤0.015 1.219 ± 0.006 ≤0.015 ≤0.015 ≤0.015 ≤0.015
09 ≤0.015 2.733 ± 0.043 ≤0.015 ≤0.015 ≤0.015 ≤0.015
10 0.023 ± 0.005 3.610 ± 0.099 ≤0.015 ≤0.015 ≤0.015 ≤0.015
14 ≤0.015 0.596 ± 0.119 ≤0.015 ≤0.015 ≤0.015 ≤0.015
15 0.088 ± 0.024 0.829 ± 0.025 ≤0.015 0.065 ± 0 ≤0.015 0.660 ± 0.077
16 ≤0.015 0.147 ± 0.036 ≤0.015 ≤0.015 ≤0.015 ≤0.015
18 ≤0.015 0.429 ± 0.021 ≤0.015 ≤0.015 ≤0.015 ≤0.015
19 0.020 ± 0.004 0.930 ± 0.031 ≤0.015 ≤0.015 ≤0.015 ≤0.015
21 ≤0.015 9.79 ± 0.127 ≤0.015 ≤0.015 ≤0.015 ≤0.015
22 0.110 ± 0.045 1.937 ± 0.019 ≤0.015 ≤0.015 ≤0.015 ≤0.015
25 2.603 ± 0.163 3.767 ± 0.273 ≤0.015 ≤0.015 ≤0.015 ≤0.015
26 ≤0.015 2.119 ± 0.023 ≤0.015 ≤0.015 ≤0.015 ≤0.015
27 ≤0.015 0.380 ± 0.012 ≤0.015 ≤0.015 ≤0.015 ≤0.015
28 ≤0.015 0.662 ± 0.013 ≤0.015 ≤0.015 ≤0.015 ≤0.015
29 ≤0.015 0.119 ± 0.013 ≤0.015 0.072 ± 0.030 ≤0.015 ≤0.015
32 0.041 ± 0.005 0.163 ± 0.036 ≤0.015 ≤0.015 ≤0.015 ≤0.015
34 0.028 ± 0.033 0.035 ± 0.011 ≤0.015 ≤0.015 ≤0.015 ≤0.015
37 0.048 ± 0.003 0.231 ± 0.047 ≤0.015 ≤0.015 ≤0.015 ≤0.015
Data are reported as means ± SD representative of 2-4 experiments. The hybridoma clones were stimulated
in the presence of antigen presenting cells (APC) and trans-sialidase (TS) recombinant protein (10 µg/mL)
and the supernatants were tested as previously described (28).
PCR allowed us to design specific primers
for the amplification of the α and ß variable
regions of hybridoma 09.
cDNA from hybridoma 09 was utilized
as template for RT-PCR using specific prim-
ers for the α chain gene or ß chain gene. The
nucleic acid and deduced amino acid se-
quences revealed that the clone representing
the TCR α chain transcript contained the
TCRAV18S2 variable region and the
TCRAJ17 junctional region (Figure 2A). The
clone representing the TCR ß chain tran-
script contained the TCRBV6S19 variable
region and TCRBJ1S1 junctional region (Fig-
ure 2B). These results confirmed the data
obtained by the NPA-PCR method described
above.
To confirm the presence of the TCRBV06
gene product on the surface of hybridoma
09, we stained these cells with an antibody
specific for murine Vß6 (RR4-7). As shown
in Figure 3, the fluorescent geometric mean
of hybridoma 09 was ten times higher than
in non-labeled cells or control cells (BWα-
ß-). The detection of the receptor on the
surface of hybridoma 09 confirmed that the
ß chain gene of the TCR is in fact being
functionally expressed as a protein on the
surface of the hybridoma cells.
Discussion
In the present study, we established and
characterized T-cell hybridomas specific for
TS, an immunodominant T. cruzi antigen.
We selected one CD3+ and CD4+ IFN-γ-
secreting T-cell hybridoma to test whether
we could use the NPA-PCR method to easily
identify its TCR transcripts. We demonstrated
that the NPA-PCR method can be useful to
rapidly and efficiently determine the vari-
able regions of both TCR transcripts of this
T-cell hybridoma. These observations are
important because a number of advantages
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Figure 1. Expression of surface
molecules in hybridomas (H) 09,
10, 21 and 26. T-cell hybrido-
mas indicated at the top of the
figure were stained with mAbs
specific for the surface markers
indicated, followed by FITC-con-
jugated goat anti-hamster (sec-
ondary) or FITC-conjugated goat
anti-rat (secondary 2) antibody,
and analyzed by FACS. The
relative geometric mean fluores-
cence obtained with each mAb
is indicated in the right upper
corner of each histogram. TCR
= T-cell receptor.
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Figure 2. Deduced amino acid
sequence of TCR α and ß chains
from hybridoma 09. Representa-
tion of sequences obtained from
TCR-H09 of α chain containing
the TCRAV18S2 variable seg-
ment, TCRAJ17 junctional seg-
ment and constant region 1 (A)
and ß chain containing the
TCRBV6S19 variable region,
TCRD diversity region, TCRBJ1S1
junctional region, and constant
region (B).
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can be credited to this methodology. First,
the NPA-PCR method uses the same re-
agents (primers) for the identification of TCR
transcripts of any T-cell clone or hybridoma.
Second, these primers are much more reli-
able and less expensive than the specific
monoclonal antibodies used for the identifi-
cation of TCR. Third, because a number of
antibodies specific for the TCR Vα families
are not available, the screening using specif-
ic antibodies may end up being useless. Fi-
nally, this method does not require the labo-
rious generation and screening of cDNA
libraries.
On the basis of these demonstrated ad-
vantages, we believe that this methodology
can significantly contribute to the identifica-
tion of TCR from T-cell hybridomas or
clones, that can be used to generate TCR-
transgenic mice. More specifically, in our
case, the TCR genes isolated from hybri-
doma 09 may allow us to establish a TCR
transgenic mouse specific for an immuno-
dominant T. cruzi antigen.
Figure 3. Expression of Vß6 on the surface of hybridoma (H) 09. H09 and BWα-ß-cells were
stained with an FITC-labeled mAb specific for murine Vß6. The relative geometric mean
fluorescences are indicated in the right upper corner of each histogram.
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